References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReturn-To-Play criteria after hamstring injury: actual medicine practice in professional soccer
Delvaux, François ULg; Rochcongar, Pierre; Bruyère, Olivier ULg et al

Poster (2013, April 25)

Detailed reference viewed: 189 (14 ULg)
Full Text
Peer Reviewed
See detailComparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria
Bruyère, Olivier ULg; Fossi, Martin; Zegels, Brigitte ULg et al

in Rheumatology International (2013), 33(4), 973-8

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is ... [more ▼]

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is a retrospective study based on data from 1,000 women randomly selected from an outpatient hospital specialized in bone metabolism in Belgium. Proportions of potentially refunded treatments between FRAX and current criteria were compared. Out of the 1,000 women files, 890 have sufficient information to assess FRAX . In Belgium, current criteria include a bone mineral density (BMD) T score below -2.5 at the lumbar spine, the femoral neck or the total hip and/or at least a prevalent vertebral fracture. Using these criteria, 167 women (18.8 %) would have access to reimbursement. Using the criteria based on the validated Belgian FRAX tool, only 116 women (13.0 %) would have access to reimbursement, meaning that access to reimbursement based on FRAX criteria would reduce by 30 % the anti-osteoporosis drug expenses covered by the national social security. Interestingly, only 65 women out of the 116 (56.0 %) selected with the FRAX criteria were also selected with the current criteria of the national social security. A substantial proportion of individuals that would potentially receive a reimbursement for their treatment using the FRAX criteria do not have access to any refund for their treatment with the current criteria. Since patients identified with the FRAX tool are those with the highest risk profile for future fractures, reappraisals of treatment reimbursement guidelines are expected in Belgium. [less ▲]

Detailed reference viewed: 35 (19 ULg)
Full Text
Peer Reviewed
See detailSafety concerns with the long-term management of osteoporosis
Reginster, Jean-Yves ULg; Pelousse, Franz; Bruyère, Olivier ULg

in Expert Opinion on Drug Safety (2013), 12(4), 507-22

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be ... [more ▼]

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be associated with a positive benefit-risk balance. Areas covered: In this descriptive review, the long-term safety of calcitonin, selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab and strontium ranelate was reviewed based on randomized controlled trials of 3 years or longer supplemented by extension study data and data from large, observational studies. Expert opinion: Rare adverse events become apparent with all currently available treatments for osteoporosis with long-term therapy. Due to the rarity of these adverse events and to the worldwide burden of osteoporosis, the benefit- risk balance remains in favor of the beneficial effects of treatment on an outcome rather than the probability of an adverse effect. No single antiosteoporosis agent is appropriate for all patients. Treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations. [less ▲]

Detailed reference viewed: 19 (9 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Rheumatology International (2013), 33(4), 979-83

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in ... [more ▼]

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in their daily practice. A survey has been conducted as part of a screening campaign for various diseases. The primary objective of the present study was to assess the perception and the knowledge of the FRAX tool by GPs. The secondary objective was to assess the impact of an information brochure about the FRAX tool on these outcomes. The survey was sent to a sample of 700 GPs after only half of them had received the information brochure. The survey results show that, out of the 193 doctors who responded to the survey, one-third know the FRAX tool but less than 20 % use it in their daily clinical practice. Among those who use it, the FRAX tool is largely seen as a complementary but not as an essential tool in the diagnosis or in the management of osteoporosis. It appears that the brochure could improve the knowledge of the FRAX tool but it would not be more efficient on its use in daily practice than the other sources of information. At present, the use of the FRAX tool in Belgium is limited but an information brochure could have a positive impact on the knowledge of the FRAX tool. [less ▲]

Detailed reference viewed: 23 (11 ULg)
Full Text
Peer Reviewed
See detailRole of nutraceuticals in the symptomatic and structural management of osteoarthritis
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 82-83

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailNonpharmacological management
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 76

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailReproducibility of joint space width assessment when external calibration on the radiograph is missing
DEROISY, Rita ULg; Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 379

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailValidity of the French hip and knee replacement expectations surveys
NEUPREZ, Audrey ULg; François, Garance ULg; Delcour, JP et al

in Osteoporosis International (2013, April), 24(Suppl.1), 374

Detailed reference viewed: 39 (20 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the impact of a 6-month training by whole body vibration on the risk of falls among nursing home residents
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Demonceau, Marie ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 246-247

Detailed reference viewed: 34 (13 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics of patients responsive to whole body vibration
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Maquet, Didier ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 243

Detailed reference viewed: 41 (11 ULg)
Full Text
Peer Reviewed
See detailQuantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study
Bruyère, Olivier ULg; Detalle, Anne-Sophie; Demonceau, Marie ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 210

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailChanges in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period
Bruyère, Olivier ULg; Cooper, Cyrus; Pavelka, Karel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 209

Detailed reference viewed: 36 (17 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Rabenda, Véronique ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 198

Detailed reference viewed: 33 (5 ULg)
Full Text
Peer Reviewed
See detailWhat is the predictive value of MRI for the occurrence of hard clinical endpoints in knee osteoarthritis?
Pelletier, Jean-Pierre; Peterfy, Charles; Brandi, Maria Luisa et al

in Osteoporosis International (2013, April), 24(Suppl.1), 84-85

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailHealth economics in osteoarthritis
Hiligsmann, Mickaël ULg; Cooper, Cyrus; Arden, Nigel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 79-80

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailWhat is the value of biomarkers for drug development in osteoarthritis?
Lotz, Martin; Martel-Pelletier, Johanne; Christiansen, Claus et al

in Osteoporosis International (2013, April), 24(Suppl.1), 77-78

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailQuality of life in sarcopenia and frailty
Rizzoli, René; Reginster, Jean-Yves ULg; Arnal, Jean-François et al

in Osteoporosis International (2013, April), 24(Suppl.1), 76-77

Detailed reference viewed: 39 (13 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study
Bruyère, Olivier ULg; Richette, P; Bellamy, N et al

in Osteoporosis International (2013, April), 24(Suppl.1), 49-51

Detailed reference viewed: 34 (4 ULg)
Full Text
Peer Reviewed
See detailCreatinine - or cystatin C - based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Moranne, Olivier et al

in BMC Nephrology (2013), 14

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the ... [more ▼]

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the Modified Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study. Recently, new equations based either on cystatin C (CKD-EPI Cys) or both cystatin and creatinine (CKD-EPI mix) have been proposed by the CKD-EPI consortium. The aim of this study was to measure the difference in the prevalence of stage 3 CKD, defined as an estimated GFR less than 60 mL/min/1.73 m2, in a population using these four equations. METHODS: CKD screening was performed in the Province of Liege, Belgium. On a voluntary basis, people aged over 50 years have been screened. GFR was estimated by the four equations. Stage 3 CKD was defined as a GFR less than 60 mL/min/1.73 m2. RESULTS: The population screened consisted of 4189 people (47% were men, mean age 63 +/- 7y). Their mean serum creatinine and plasma cystatin C levels were 0.88 +/- 0.21 mg/dL and 0.85 +/- 0.17 mg/L, respectively. The prevalence of CKD in this population using the MDRD, the CKD-EPI, the CKD-EPI Cys and the CKD-EPI mix equations was 13%, 9.8%, 4.7% and 5%, respectively. The prevalence of CKD was significantly higher with the creatinine-based (MDRD and the CKD-EPI) equations compared to the new cystatin C-based equations. CONCLUSIONS: Prevalence of CKD varies strongly depending on the method used to estimate GFR. Such discrepancies are of importance and must be confirmed and explained by additional studies, notably by studies using GFR measured with a reference method [less ▲]

Detailed reference viewed: 50 (19 ULg)